Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s): VYYRF

Healthcare Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > From 21 Dec 2023 PR

<< Previous

Bullboard Posts

Next >>

Post by WarrantOfficeron Jan 02, 2024 9:19am

128 Views

Post# 35806792

From 21 Dec 2023 PR

"Voyageur is in talks currently with potential drug development research firms to launch the drug development program. However, their clinical adoption is contingent upon continued research, clinical validation to confirm their safety and efficacy and regulatory approvals"

I assume when Voyageur states "their clinical adaptation" they are in fact refering to the drug development research firms.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments